Pricing Log in Create free account
Friday 6 November 2026 Export PCVX’s income statement to Excel — free account

Vaxcyte, Inc.

PCVX Healthcare Biotechnology

EPS
−61.5%
Free cash flow
−92.6%

Quarter to June 2026, against a year earlier

64.23 2.31 +3.73%
Market cap
$9.8B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Vaxcyte, Inc. (PCVX) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 34 added · 6 removed · 56 modified
P2I1A: 20 added · 3 removed · 79 modified 		Short cash runway Share dilution
8-K Nov 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 6, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Oct 5, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 31, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Officer departure
10-Q Jun 30, 2026 P1I2: 7 added · 10 removed · 46 modified
P2I1A: 1 added · 2 removed · 79 modified
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 13, 2026 5.02 Departure or appointment of directors or officers
8-K Jun 17, 2026 5.02 Departure or appointment of directors or officers
8-K Jun 15, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K May 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 24, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 52 added · 37 removed · 133 modified
1A: 19 added · 10 removed · 134 modified
7: 53 added · 21 removed · 52 modified
8-K Feb 24, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 29, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Dec 18, 2025 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 24, 2025 1.01 Entry into a material definitive agreement
10-Q Jun 30, 2025
8-K Aug 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 25, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 5, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 27, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 6, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.